Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $23,157 | $29,818 | $191,130 | $130,629 |
| - Cash | $19,526 | $16,429 | $40,556 | $23,763 |
| + Debt | $116 | $138 | $172 | $205 |
| Enterprise Value | $3,747 | $13,527 | $150,746 | $107,071 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$10,257 | -$11,401 | -$14,951 | -$16,123 |
| % Margin | – | – | – | – |
| Net Income | -$9,820 | -$22,507 | -$14,871 | -$16,136 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.3 | -0.68 | -0.47 | -0.51 |
| % Growth | 55.9% | -44.7% | 7.8% | – |
| Operating Cash Flow | -$11,385 | -$12,094 | -$13,419 | -$11,686 |
| Capital Expenditures | $0 | -$137 | $0 | -$311 |
| Free Cash Flow | -$11,385 | -$12,231 | -$13,419 | -$11,997 |